drugset
drugset / Trial / NCT02282605

Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects

NCT02282605 ↗

Phase 1/2 Completed 60 enrolled Destiny Pharma Plc
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to determine the efficacy, safety and tolerability of two concentrations of XF-73 nasal gel in combination with body and face washing with chlorhexidine gluconate cloths in eradicating nasal carriage of Staphylococcus aureus.

Timeline

Start
2014-09
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject EXEPORFINIUM Other / unclassified 0.3 mg Intranasal
Subject EXEPORFINIUM Other / unclassified 1.2 mg Intranasal

Indications

staphylococcus aureus infection